Posterior-Inferior Intra-articular Cortical Piercing Titanium Implant for Sacroiliac Joint Fusion: Evaluation of Safety and Effectiveness Outcomes (PIERCE)
Posterior-Inferior Intra-articular Cortical PiERcing Titanium Implant for SaCroiliac Joint Fusion: Evaluation of Safety and Effectiveness Outcomes
The purpose of this study is to evaluate outcomes in patients treated with iFuse INTRA Ti for chronic SI joint pain.
研究概览
详细说明
PIERCE is a prospective, multicenter, post-market observational study evaluating the safety, performance, and efficacy of iFuse INTRA Ti.
研究类型
注册 (估计的)
联系人和位置
学习联系方式
- 姓名:Director of Clinical Affairs
- 电话号码:408-207-0700
- 邮箱:clinicalaffairs.@si-bone.com
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
Patients with sacroiliac joint (SIJ) dysfunction due to degenerative sacroiliitis or sacroiliac joint disruption for at least 6 months refractory to non-surgical care
描述
Inclusion Criteria:
- Age > 21 years.
- Patient has chronic lower back pain (≥6 months) refractory to non-surgical care.
- Diagnosis of sacroiliac joint dysfunction (degenerative sacroiliitis or SIJ disruption) and scheduled to be treated with INTRA Ti.
- Patient has SIJ pain of at least 5 on a 0-10 numeric rating scale (NRS) prior to procedure.
- Participant has signed study-specific informed consent form.
Exclusion Criteria:
- ASA score 4 or 5.
- Severe back pain due to other causes, such as lumbar disc degeneration, lumbar disc herniation, lumbar spondylolisthesis, lumbar spinal stenosis, lumbar facet degeneration, and lumbar vertebral body fracture.
- Other known sacroiliac pathology such as: inflammatory sacroiliitis (e.g., ankylosing spondylitis or other HLA-associated spondyloarthropathy), tumor, infection, acute fracture.
- Current diagnosis of cluneal neuralgia.
- Previous SIJ implant placement, including allograft, on the treated (index) side.
- Anatomic anomalies/defects that would preclude safe and/or biomechanically acceptable device placement.
- History of recent (<1 year) major trauma to pelvis.
- Previously diagnosed or suspected severe osteoporosis (defined as prior T-score < -2.5 or history of osteoporotic fracture).
- Chronic rheumatologic condition (e.g., rheumatoid arthritis).
- Current diagnosis of fibromyalgia.
- Known allergy to titanium or titanium alloys.
- Current local or systemic infection that raises the risk of surgery.
- Patient currently receiving or seeking worker's compensation, disability remuneration, and/or involved in injury litigation.
- Currently pregnant or planning pregnancy in the next 2 years (self-reported).
- Patient is a prisoner or a ward of the state.
- Known or suspected active drug or alcohol abuse, including opioids
- Diagnosed psychiatric disease (e.g., schizophrenia, major depression, personality disorders) that could interfere with study participation.
学习计划
研究是如何设计的?
设计细节
- 观测模型:CASE_ONLY
- 时间观点:PROSPECTIVE
队列和干预
团体/队列 |
干预/治疗 |
|---|---|
|
SIJ Dysfunction treated with INTRA Ti
Patients with sacroiliac joint (SIJ) dysfunction due to various causes refractory to non-surgical management. |
FDA-cleared implant used for fusion of the sacroiliac joint (SIJ) for SIJ dysfunction, that is a direct result of SIJ disruption and degenerative sacroiliitis. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Composite endpoint of safety and performance
大体时间:6 months.
|
The participant is considered a success if all the following criteria are met:
|
6 months.
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Proportion of Participants with a Serious Adverse Event (SAE)
大体时间:24 months
|
Proportion of participants with a serious adverse event classified as probably or definitely related to the study device or procedure |
24 months
|
|
Proportion of Participants with ≥1 Subsequent Surgical Intervention(s) (SSI)
大体时间:24 months
|
Proportion of participants undergoing one or more SSI related to the index procedure. |
24 months
|
|
Proportion of Treated Sides with Radiographic Evidence of Loosening
大体时间:24 months
|
Proportion of treated sides showing signs of loosening of INTRA Ti, as evidenced by both radiolucent areas around implant plus bony reaction ("rind") near implant. |
24 months
|
|
Proportion of Implants with Radiographic Evidence of Device Migration.
大体时间:24 months
|
Proportion of INTRA Ti implants that show evidence of device migration. |
24 months
|
|
Proportion of Implants with Radiographic Evidence of Device Breakage.
大体时间:24 months
|
Proportion of INTRA Ti implants that show breakage. |
24 months
|
|
Proportion of Participants with Radiographic Evidence of Fusion
大体时间:24 months
|
Bony apposition to the implant at 12 months as evaluated by pelvic CT |
24 months
|
合作者和调查者
调查人员
- 研究主任:Stacie Tran, MPH、SI-BONE
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
There are currently no plans to share but IPD may be shared with qualified researchers upon reasonable request, subject to sponsor approval and data use agreements.
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
在美国制造并从美国出口的产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.